OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
André Scheen
Diabetes & Metabolism (2021) Vol. 47, Iss. 6, pp. 101275-101275
Closed Access | Times Cited: 26
Showing 1-25 of 26 citing articles:
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Jingqian Su, Yingsheng Luo, Shan Hu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13381-13381
Open Access | Times Cited: 46
Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 17, pp. 6671-6671
Open Access | Times Cited: 28
Ema Schönberger, Vjera Mihaljević, Kristina Steiner, et al.
International Journal of Environmental Research and Public Health (2023) Vol. 20, Iss. 17, pp. 6671-6671
Open Access | Times Cited: 28
Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
André Scheen, Fabrice Bonnet
Diabetes & Metabolism (2023) Vol. 49, Iss. 2, pp. 101419-101419
Open Access | Times Cited: 20
Nocturnal hypoglycemia is underdiagnosed in older people with insulin‐treated type 2 diabetes: The HYPOAGE observational study
Anne‐Sophie Boureau, Béatrice Guyomarch, Pierre Gourdy, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2107-2119
Open Access | Times Cited: 17
Anne‐Sophie Boureau, Béatrice Guyomarch, Pierre Gourdy, et al.
Journal of the American Geriatrics Society (2023) Vol. 71, Iss. 7, pp. 2107-2119
Open Access | Times Cited: 17
Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach
Laura M. Güdemann, Katie G. Young, Nicholas J. Thomas, et al.
Diabetologia (2024)
Open Access | Times Cited: 5
Laura M. Güdemann, Katie G. Young, Nicholas J. Thomas, et al.
Diabetologia (2024)
Open Access | Times Cited: 5
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study
Tanvi Patil, Morgan Cook, Jesse Hobson, et al.
The American Journal of Cardiology (2023) Vol. 201, pp. 281-293
Closed Access | Times Cited: 12
Tanvi Patil, Morgan Cook, Jesse Hobson, et al.
The American Journal of Cardiology (2023) Vol. 201, pp. 281-293
Closed Access | Times Cited: 12
Study of the prescription pattern of antidiabetics in hypertension with diabetes patients in geriatric population at tertiary care centre: a retrospective observational study
Aparna Pal, Mirza S. Baig, Shailaja V Rao
International Journal of Research in Medical Sciences (2025) Vol. 13, Iss. 3, pp. 1051-1058
Open Access
Aparna Pal, Mirza S. Baig, Shailaja V Rao
International Journal of Research in Medical Sciences (2025) Vol. 13, Iss. 3, pp. 1051-1058
Open Access
Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: A comprehensive review ranging from sulphonylureas to SGLT2 inhibitors
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101405-101405
Closed Access | Times Cited: 17
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101405-101405
Closed Access | Times Cited: 17
Skin-Related Adverse Reactions Induced by Oral Antidiabetic Drugs—A Review of Literature and Case Reports
Justyna Kowalska, Dorota Wrześniok
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 847-847
Open Access | Times Cited: 3
Justyna Kowalska, Dorota Wrześniok
Pharmaceuticals (2024) Vol. 17, Iss. 7, pp. 847-847
Open Access | Times Cited: 3
Clinical pharmacology of antidiabetic drugs: What can be expected of their use?
André Scheen
La Presse Médicale (2022) Vol. 52, Iss. 1, pp. 104158-104158
Closed Access | Times Cited: 12
André Scheen
La Presse Médicale (2022) Vol. 52, Iss. 1, pp. 104158-104158
Closed Access | Times Cited: 12
Dipeptidyl peptidase-4 inhibitors and the risk of infection: A systematic review and meta-analysis of cardiovascular outcome trials
Na Yang, Liyun He, Peng Liu, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 5, pp. 1011-1020
Open Access | Times Cited: 2
Na Yang, Liyun He, Peng Liu, et al.
World Journal of Diabetes (2024) Vol. 15, Iss. 5, pp. 1011-1020
Open Access | Times Cited: 2
Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease
André Scheen, Pierre Delanaye
Expert Review of Endocrinology & Metabolism (2021) Vol. 17, Iss. 1, pp. 35-46
Closed Access | Times Cited: 11
André Scheen, Pierre Delanaye
Expert Review of Endocrinology & Metabolism (2021) Vol. 17, Iss. 1, pp. 35-46
Closed Access | Times Cited: 11
Management of type 2 diabetes in patients with frailty
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. 30-32
Open Access | Times Cited: 1
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. 30-32
Open Access | Times Cited: 1
A Phase I Clinical Study of the Pharmacokinetics and Safety of Prusogliptin Tablets in Subjects with Mild to Moderate Hepatic Insufficiency and Normal Liver Function
Huiting Zhang, Yicong Bian, Weifeng Zhao, et al.
Current Drug Metabolism (2024) Vol. 25, Iss. 2, pp. 140-151
Closed Access | Times Cited: 1
Huiting Zhang, Yicong Bian, Weifeng Zhao, et al.
Current Drug Metabolism (2024) Vol. 25, Iss. 2, pp. 140-151
Closed Access | Times Cited: 1
Safety and effectiveness of SGLT2-inhibitors in people with type 2 diabetes over 70: UK population-based study using an Instrumental Variable approach
Laura M. Güdemann, Katherine Young, Nicholas J. Thomas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Laura M. Güdemann, Katherine Young, Nicholas J. Thomas, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Prise en charge du diabète de type 2 chez les patients fragiles
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. e10-e13
Open Access
Kara Hawker, Ripa Akter, Frank Molnar, et al.
Canadian Family Physician (2024) Vol. 70, Iss. 1, pp. e10-e13
Open Access
The impact of dipeptidyl peptidase 4 inhibitors on health-related quality of life in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
X Y Zhang, Wai Kei Tong, Xia Qian, et al.
Quality of Life Research (2024) Vol. 33, Iss. 12, pp. 3175-3188
Closed Access
X Y Zhang, Wai Kei Tong, Xia Qian, et al.
Quality of Life Research (2024) Vol. 33, Iss. 12, pp. 3175-3188
Closed Access
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Behina Forouzanmehr, Mohammad Amin Hemmati, Stephen L. Atkin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 398, Iss. 1, pp. 351-362
Closed Access
Behina Forouzanmehr, Mohammad Amin Hemmati, Stephen L. Atkin, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 398, Iss. 1, pp. 351-362
Closed Access
Safety and Efficiency of Dipeptidyl Peptidase IV Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
Adili Tuersun, Munire Mohetaer, Guanxin Hou, et al.
Current Therapeutic Research (2024) Vol. 101, pp. 100763-100763
Open Access
Adili Tuersun, Munire Mohetaer, Guanxin Hou, et al.
Current Therapeutic Research (2024) Vol. 101, pp. 100763-100763
Open Access
Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients
Hung‐Wei Liao, Chung‐Yi Cheng, Hsing‐Yu Chen, et al.
Clinical Kidney Journal (2024) Vol. 18, Iss. 2
Open Access
Hung‐Wei Liao, Chung‐Yi Cheng, Hsing‐Yu Chen, et al.
Clinical Kidney Journal (2024) Vol. 18, Iss. 2
Open Access
Recent Advances in the Treatment of Diabetes in the Elderly
Hakyoung Park, Hun‐Sung Kim
(2024) Vol. 25, Iss. 3, pp. 129-134
Closed Access
Hakyoung Park, Hun‐Sung Kim
(2024) Vol. 25, Iss. 3, pp. 129-134
Closed Access
Prescriptions of newer glucose regulating agents in older hospitalized patients with type 2 diabetes A retrospective cohort study
D. Janssen, Carolien M. J. van der Linden, Maarten J. Deenen, et al.
Diabetes Epidemiology and Management (2023) Vol. 12, pp. 100157-100157
Open Access
D. Janssen, Carolien M. J. van der Linden, Maarten J. Deenen, et al.
Diabetes Epidemiology and Management (2023) Vol. 12, pp. 100157-100157
Open Access
New perspectives in the treatment of heart failure: The role of SGLT2 inhibitors
Riber Fabián Donoso Noroña, Nairovys Gómez Martínez, Adisnay Rodríguez-Plasencia
Salud Ciencia y Tecnología - Serie de Conferencias (2023) Vol. 2, pp. 769-769
Closed Access
Riber Fabián Donoso Noroña, Nairovys Gómez Martínez, Adisnay Rodríguez-Plasencia
Salud Ciencia y Tecnología - Serie de Conferencias (2023) Vol. 2, pp. 769-769
Closed Access
Choix entre une gliptine et une gliflozine chez le patient âgé avec un diabète de type 2
André Scheen
Médecine des Maladies Métaboliques (2022) Vol. 16, Iss. 3, pp. 264-270
Closed Access
André Scheen
Médecine des Maladies Métaboliques (2022) Vol. 16, Iss. 3, pp. 264-270
Closed Access
